For informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.
Price · 1Y
$544.51
Thesis
Madrigal commercializes Rezdiffra, the first FDA-approved therapy for MASH (formerly NASH) — a large, previously untreated metabolic-liver-disease market. As the first mover with an oral, liver-biopsy-validated drug, it holds the category lead while the launch ramps across hepatology and endocrinology.
The investment case is a first-in-class commercial leader in a multi-billion-dollar metabolic market with high unmet need. Risks: it is effectively a single-product company, so the launch curve is the whole story; GLP-1s (which also improve liver endpoints) loom as both competition and potential combination partners, and reimbursement breadth governs uptake.
Catalysts
- Rezdiffra prescription and revenue ramp
- Label expansion (e.g. compensated cirrhosis)
- GLP-1 competitive and combination dynamics
- Payer coverage and prior-authorization trends
Recent events
Material filings, federal awards, and regulatory activity. Impact is scored against market cap.
- Jul 8OtherClinicalTrials.gov
Phase 3 MAESTRO-NASH-OUTCOMES trial (NCT05500222) for resmetirom in NASH cirrhosis status updated to ACTIVE_NOT_RECRUITING.
- Jun 17LeadershipSEC
8-K filed disclosing items 5.02 (officer/director matters), 5.07 (shareholder vote), 9.01 (exhibits).
- Jun 16Trial initiationClinicalTrials.gov
Madrigal initiates Phase 2 trial of resmetirom in post-liver transplant MASH patients (NCT07335601, recruiting).
- Jun 4Trial readoutClinicalTrials.gov
Phase 2 trial NCT03038022 (MGL-3196 in HeFH) status updated to COMPLETED
- Jun 2OtherClinicalTrials.gov
Phase 3 trial NCT05500222 (resmetirom, NASH cirrhosis) status updated to ACTIVE_NOT_RECRUITING
- Jun 1OtherClinicalTrials.gov
Phase 3 trial NCT03900429 (resmetirom, NASH/fibrosis) status updated to ACTIVE_NOT_RECRUITING on 2026-06-01.
- May 28Trial initiationClinicalTrials.gov
Madrigal initiates Phase 2 trial of resmetirom in post-liver transplant MASH patients (NCT07335601, recruiting).
- May 6Financial resultsSEC
Madrigal Pharmaceuticals filed 8-K (items 2.02,9.01) disclosing results of operations.